NEWS AND EVENTS
All
Deerfield Announcement
Investment Partnership
Deerfield Newsletter
Access Publications here

All

April 03, 2018

Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer

Read More...
March 22, 2018

Deerfield Commits $36 Million to Advance Dracen’s Novel Immuno-Metabolism Pipeline

Read More...
March 14, 2018

Bridge Medicines Accepts Novel Small Molecule Targeting Basal Cell Carcinoma As First Drug Candidate for Development

Read More...
February 13, 2018

Deerfield acquires ReMed alongside Baird Capital

Read More...
January 04, 2018

Bluefield Innovations Pursues Broadly Applicable Cancer Target

Read More...